Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Aug;62(2):319–323. doi: 10.1038/bjc.1990.286

Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group.

C R Pinkerton 1, J M Zucker 1, O Hartmann 1, J Pritchard 1, V Broadbent 1, P Morris-Jones 1, F Breatnach 1, A E Craft 1, A D Pearson 1, K R Wallendszus 1, et al.
PMCID: PMC1971805  PMID: 2386751

Abstract

Fifty-one children, aged from 15 months to 13 years 5 months with metastatic neuroblastoma presenting sequentially at the participating institutions received four 3 to 4 weekly courses of high dose multiagent chemotherapy. High dose cisplatin (200 mg m-2) combined with etoposide (500 mg m-2), HIPE, was alternated with ifosfamide (9 g m-2), vincristine (1.5 mg m-2), and adriamycin (60 mg m-1), IVAd. Disease status was re-evaluated 3 to 4 weeks after the fourth course and the response classified according to the International Neuroblastoma Response Criteria (INRC). The overall response rate in evaluable patients was 55% and response rates by site were: bone marrow 67% (complete response 47%); bone scan 68%; primary tumour 61%, and urinary catecholamine metabolites (VMA/HVA) 95%. Serial 51Cr EDTA renal clearance studies showed a glomerular filtration rate (GFR) decline in 40% of patients but in only seven cases to below 50% of the pretreatment value. There was no instance of renal failure during induction, though two patients developed severe renal failure following 'megatherapy' given to consolidate remission. Serial audiometry showed a significant decline in hearing at frequencies above 2,000 Hz in 37% of children but at or below 2,000 Hz in only 17%. Neutropenia and thrombocytopenia were severe and intravenous antibiotics were required after 30% of courses. Each of two treatment-related deaths occurred during pancytopenia following courses of IVAd. Complete, or greater than 90%, removal of primary site tumour was possible in 70% of cases following this induction regimen and 75% of patients proceeded to elective megatherapy within a median time of 24 weeks after diagnosis. This short intensive induction programme is highly effective at achieving cytoreduction, enabling early surgery and early megatherapy procedures. It is, however, too early to draw firm conclusions about the impact of this approach to treatment on the cure rate.

Full text

PDF
319

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernard J. L., Philip T., Zucker J. M., Frappaz D., Robert A., Margueritte G., Boilletot A., Philippe N., Lutz P., Roche H. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen? J Clin Oncol. 1987 Dec;5(12):1952–1959. doi: 10.1200/JCO.1987.5.12.1952. [DOI] [PubMed] [Google Scholar]
  2. Brock P., Pritchard J., Bellman S., Pinkerton C. R. Ototoxicity of high-dose cis-platinum in children. Med Pediatr Oncol. 1988;16(5):368–369. doi: 10.1002/mpo.2950160517. [DOI] [PubMed] [Google Scholar]
  3. Cavalli F., Sonntag R. W., Jungi F., Senn H. J., Brunner K. W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 1978 Mar;62(3):473–475. [PubMed] [Google Scholar]
  4. Finklestein J. Z., Klemperer M. R., Evans A., Bernstein I., Leikin S., McCreadie S., Grosfeld J., Hittle R., Weiner J., Sather H. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Med Pediatr Oncol. 1979;6(2):179–188. doi: 10.1002/mpo.2950060211. [DOI] [PubMed] [Google Scholar]
  5. Hartmann O., Benhamou E., Beaujean F., Kalifa C., Lejars O., Patte C., Behard C., Flamant F., Thyss A., Deville A. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol. 1987 Aug;5(8):1205–1211. doi: 10.1200/JCO.1987.5.8.1205. [DOI] [PubMed] [Google Scholar]
  6. Hartmann O., Pinkerton C. R., Philip T., Zucker J. M., Breatnach F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988 Jan;6(1):44–50. doi: 10.1200/JCO.1988.6.1.44. [DOI] [PubMed] [Google Scholar]
  7. Hayes F. A., Green A. A., Casper J., Cornet J., Evans W. E. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer. 1981 Oct 15;48(8):1715–1718. doi: 10.1002/1097-0142(19811015)48:8<1715::aid-cncr2820480805>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  8. Kellie S. J., De Kraker J., Lilleyman J. S., Bowman A., Pritchard J. Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group. Eur J Cancer Clin Oncol. 1988 May;24(5):903–908. doi: 10.1016/0277-5379(88)90200-3. [DOI] [PubMed] [Google Scholar]
  9. Kushner B. H., Helson L. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients. J Clin Oncol. 1987 Nov;5(11):1746–1751. doi: 10.1200/JCO.1987.5.11.1746. [DOI] [PubMed] [Google Scholar]
  10. Ninane J., Pritchard J., Malpas J. S. Chemotherapy of advanced neuroblastoma: does adriamycin contribute? Arch Dis Child. 1981 Jul;56(7):544–548. doi: 10.1136/adc.56.7.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nitschke R., Cangir A., Crist W., Berry D. H. Intensive chemotherapy for metastatic neuroblastoma: a Southwest Oncology Group study. Med Pediatr Oncol. 1980;8(3):281–288. doi: 10.1002/mpo.2950080310. [DOI] [PubMed] [Google Scholar]
  12. Philip T., Bernard J. L., Zucker J. M., Pinkerton R., Lutz P., Bordigoni P., Plouvier E., Robert A., Carton R., Philippe N. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J Clin Oncol. 1987 Feb;5(2):266–271. doi: 10.1200/JCO.1987.5.2.266. [DOI] [PubMed] [Google Scholar]
  13. Philip T., Ghalie R., Pinkerton R., Zucker J. M., Bernard J. L., Leverger G., Hartmann O. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1987 Jun;5(6):941–950. doi: 10.1200/JCO.1987.5.6.941. [DOI] [PubMed] [Google Scholar]
  14. Pinkerton C. R., Rogers H., James C., Bowman A., Barbor P. R., Eden O. B., Pritchard J. A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol. 1985;15(3):258–262. doi: 10.1007/BF00263897. [DOI] [PubMed] [Google Scholar]
  15. Pritchard J., Gordon I., Lashford L., Dicks-Mireaux C. Specificity of iodobenzylguanidine scanning in neuroblastoma. Lancet. 1988 Feb 27;1(8583):479–479. doi: 10.1016/s0140-6736(88)91279-2. [DOI] [PubMed] [Google Scholar]
  16. Rosen E. M., Cassady J. R., Frantz C. N., Kretschmar C., Levey R., Sallan S. E. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. J Clin Oncol. 1984 Jul;2(7):719–732. doi: 10.1200/JCO.1984.2.7.719. [DOI] [PubMed] [Google Scholar]
  17. Shafford E. A., Rogers D. W., Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol. 1984 Jul;2(7):742–747. doi: 10.1200/JCO.1984.2.7.742. [DOI] [PubMed] [Google Scholar]
  18. de Kraker J., Pritchard J., Hartmann O., Ninane J. Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. Pediatr Hematol Oncol. 1987;4(2):101–104. doi: 10.3109/08880018709141255. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES